Cargando…

The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination

Development of effective HIV-1 vaccines requires synergy between innate and adaptive immune cells. We show that induction of the transcription factor CREB1 and its target genes by the recombinant canarypox vector ALVAC+Alum augments immunogenicity in Non-human primates (NHPs) and predicts reduced HI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomalka, Jeffrey Alan, Pelletier, Adam Nicolas, Fourati, Slim, Latif, Muhammad Bilal, Sharma, Ashish, Furr, Kathryn, Carlson, Kevin, Lifton, Michelle, Gonzalez, Ana, Wilkinson, Peter, Franchini, Genoveffa, Parks, Robert, Letvin, Norman, Yates, Nicole, Seaton, Kelly, Tomaras, Georgia, Tartaglia, Jim, Robb, Merlin, Michael, Nelson, Koup, Richard, Haynes, Barton, Santra, Sampa, Sekaly, Rafick Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525330/ https://www.ncbi.nlm.nih.gov/pubmed/34556879 http://dx.doi.org/10.1038/s41590-021-01026-9

Ejemplares similares

Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
por: Vaccari, Monica, et al.
Publicado: (2019)

Engagement of monocytes, NK cells, and CD4(+) Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIV(mac251) vaginal acquisition
por: Gorini, Giacomo, et al.
Publicado: (2020)

Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines
por: Pelletier, Adam N, et al.
Publicado: (2022)

RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues
por: Liyanage, NP, et al.
Publicado: (2012)

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
por: Zolla-Pazner, Susan, et al.
Publicado: (2013)

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2019)

Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2020)

P19-51 LB. Improvement of the efficacy of ALVAC-HIV vaccine candidates for humans in non human primates
por: Franchini, G
Publicado: (2009)

Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center
por: Eslamizar, Leila, et al.
Publicado: (2021)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
por: Fourati, Slim, et al.
Publicado: (2019)

ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study
por: Saba, Corey, et al.
Publicado: (2022)

Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells
por: Harenberg, Anke, et al.
Publicado: (2008)

A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells
por: Eller, Michael A., et al.
Publicado: (2011)

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
por: Sekaly, Rafick-Pierre
Publicado: (2008)

Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
por: Herrera, Carolina, et al.
Publicado: (2022)

Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques
por: Negri, Donatella, et al.
Publicado: (2016)

Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies
por: Ma, Ben-Jiang, et al.
Publicado: (2011)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
por: Moodie, Zoe, et al.
Publicado: (2020)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
por: Bolton, Diane L., et al.
Publicado: (2012)

ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone
por: Costanzo, Margaret C., et al.
Publicado: (2023)

Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/E
por: Ratto-Kim, Silvia, et al.
Publicado: (2015)

Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41
por: Dennison, S. Moses, et al.
Publicado: (2011)

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
por: O'Connell, RJ, et al.
Publicado: (2012)

Comparison of the depth of vaccine-elicited HIV-1 Env epitope-specific CD8+ T lymphocyte responses
por: Hulot, SL, et al.
Publicado: (2012)

Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2011)

The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy)
por: Angel, Jonathan B., et al.
Publicado: (2015)

HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC
por: Bissa, Massimiliano, et al.
Publicado: (2023)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination
por: Fourati, Slim, et al.
Publicado: (2016)

Paracrine Transfer of Mouse Mammary Tumor Virus Superantigen
por: Delcourt, Marc, et al.
Publicado: (1997)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

Anisocytosis is Associated With Short-Term Mortality in COVID-19 and May Reflect Proinflammatory Signature in Uninfected Ambulatory Adults
por: Hornick, Andrew, et al.
Publicado: (2020)

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection
por: LATIF, MUHAMMAD BILAL, et al.
Publicado: (2022)

Early Activation of Caspases during T Lymphocyte Stimulation Results in Selective Substrate Cleavage in Nonapoptotic Cells
por: Alam, Antoine, et al.
Publicado: (1999)

Highly Biased CDR3 Usage in Restricted Sets of β Chain Variable Regions During Viral Superantigen 9 Response
por: Ciurli, Cristina, et al.
Publicado: (1998)

A systems framework for vaccine design
por: Mooney, Michael, et al.
Publicado: (2013)

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand
por: Kaewkungwal, J, et al.
Publicado: (2009)

The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-γ by Natural Killer (NK) cells enhancing Th1 polarization
por: Ryan, Elizabeth J., et al.
Publicado: (2007)

Mosaic Vaccines Elicit CD8+ T lymphocyte Responses in Monkeys that Confer Enhanced Immune Coverage of Diverse HIV Strains
por: Santra, Sampa, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ghmr1but7tpgjc78mkj417paur